Reason for request
Inclusion on the list of medicines reimbursed by National Insurance and approved for use by hospitals in the extension of indication “relief of broncho-obstructive symptoms in patients with chronic obstructive pulmonary disease”.
Clinical Benefit
| Substantial |
Le service médical rendu par ATIMOS 12 microgrammes/dose, solution pour inhalation en flacon pressurisé est important.
|
Clinical Added Value
| no clinical added value |
ATIMOS 12 microgrammes/dose, solution pour inhalation en flacon pressurisé n'apporte pas d'amélioration du service médical rendu (ASMR V) par rapport aux autres bronchodilatateurs de longue durée d'action disponibles dans cette indication.
|
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
TWMgmA13q8eLwB2T
